| Product Code: ETC13348514 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Psychomotor Agitation Market was valued at USD 0.75 Billion in 2024 and is expected to reach USD 1.08 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The global psychomotor agitation market is driven by factors such as the increasing prevalence of mental health disorders, rising stress levels among individuals, and the growing awareness and diagnosis of psychomotor agitation. Psychomotor agitation is commonly associated with conditions like anxiety, bipolar disorder, and schizophrenia. The market is witnessing a surge in research and development activities aimed at developing effective treatment options, including pharmacological and non-pharmacological interventions. Additionally, the integration of technology, such as digital health solutions and telemedicine, is expected to propel market growth by enhancing accessibility to care. Geographically, North America and Europe are key markets due to advanced healthcare infrastructure and high adoption rates of mental health services. Emerging economies in Asia-Pacific and Latin America are also presenting lucrative opportunities for market expansion.
The Global Psychomotor Agitation Market is experiencing a growing demand for non-pharmacological interventions and alternative therapies to manage agitation in patients with various mental health conditions. There is a shift towards holistic approaches such as mindfulness, yoga, and art therapy, as well as the use of technology-driven solutions like virtual reality and telemedicine for remote monitoring and intervention. Additionally, the market is seeing an increased focus on personalized treatment plans tailored to individual patient needs, driving innovation in precision medicine and digital health tools. Opportunities lie in developing innovative non-invasive devices and digital platforms to enhance patient care and improve outcomes, as well as collaborations between healthcare providers, technology companies, and research institutions to advance the understanding and management of psychomotor agitation.
The Global Psychomotor Agitation Market faces several challenges, including limited awareness among healthcare professionals about appropriate treatment strategies, varying regulatory requirements across different regions, and the need for more effective medications with fewer side effects. Additionally, the stigma associated with mental health disorders can hinder patients from seeking help for psychomotor agitation, leading to underdiagnosis and undertreatment. Furthermore, the high cost of some treatment options and the lack of standardized protocols for managing psychomotor agitation can contribute to inconsistencies in care delivery. Overall, addressing these challenges will require a multi-faceted approach involving increased education and training for healthcare providers, improved access to affordable treatments, and continued research efforts to develop more targeted and efficient therapies for psychomotor agitation.
The Global Psychomotor Agitation Market is primarily driven by factors such as increasing prevalence of psychiatric disorders, growing awareness about mental health issues, and advancements in healthcare infrastructure. The rising stress levels and lifestyle changes leading to anxiety and agitation among individuals are also contributing to the market growth. Additionally, the availability of various treatment options, including medication and therapy, is fueling the demand for psychomotor agitation management. Moreover, the increasing research and development activities focused on developing innovative solutions for managing psychomotor agitation are expected to further drive the market in the coming years. Overall, the market growth is being propelled by a combination of factors related to mental health awareness, treatment options, and technological advancements in the healthcare sector.
Government policies related to the Global Psychomotor Agitation Market often focus on regulating the use and distribution of pharmaceuticals and treatments for managing psychomotor agitation, as well as ensuring the safety and efficacy of such products. This includes oversight by regulatory bodies such as the FDA in the United States and the EMA in Europe to approve new medications and monitor their ongoing use. Additionally, governments may implement guidelines for healthcare providers to follow when diagnosing and treating psychomotor agitation, as well as promoting research and development in this area. Policies may also address issues of accessibility and affordability of treatments to ensure that patients have adequate access to care. Overall, government policies play a crucial role in shaping the landscape of the Global Psychomotor Agitation Market to prioritize patient safety and well-being.
The Global Psychomotor Agitation Market is expected to witness steady growth in the coming years, driven by factors such as the increasing prevalence of mental health disorders and substance abuse, as well as the growing awareness and diagnosis of psychomotor agitation. Technological advancements in healthcare, such as the development of novel pharmacological treatments and non-pharmacological interventions, are also likely to contribute to market expansion. Furthermore, the rising geriatric population, who are more prone to psychomotor agitation, will fuel market demand. However, challenges such as regulatory hurdles, pricing pressures, and the impact of the COVID-19 pandemic on healthcare systems may hinder market growth to some extent. Overall, the Global Psychomotor Agitation Market is poised for growth, with opportunities for innovation and market penetration through strategic collaborations and product development.
In the global psychomotor agitation market, Asia is expected to witness significant growth due to the rising prevalence of mental health disorders and increasing awareness about the condition. North America is anticipated to dominate the market, driven by advanced healthcare infrastructure and high healthcare expenditure. Europe is also a key market, owing to the presence of established pharmaceutical companies and growing research and development activities in the region. The Middle East and Africa region is likely to experience steady growth, supported by improving healthcare facilities and increasing focus on mental health awareness. Latin America is expected to showcase moderate growth due to the rising incidence of psychomotor agitation and increasing adoption of advanced treatment options in the region.
Global Psychomotor Agitation Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Psychomotor Agitation Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Psychomotor Agitation Market Revenues & Volume, 2021 & 2031F |
3.3 Global Psychomotor Agitation Market - Industry Life Cycle |
3.4 Global Psychomotor Agitation Market - Porter's Five Forces |
3.5 Global Psychomotor Agitation Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Psychomotor Agitation Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Global Psychomotor Agitation Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.8 Global Psychomotor Agitation Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Global Psychomotor Agitation Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.10 Global Psychomotor Agitation Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Global Psychomotor Agitation Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Psychomotor Agitation Market Trends |
6 Global Psychomotor Agitation Market, 2021 - 2031 |
6.1 Global Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Psychomotor Agitation Market, Revenues & Volume, By Antipsychotics, 2021 - 2031 |
6.1.3 Global Psychomotor Agitation Market, Revenues & Volume, By Antidepressants, 2021 - 2031 |
6.1.4 Global Psychomotor Agitation Market, Revenues & Volume, By Anticonvulsants, 2021 - 2031 |
6.1.5 Global Psychomotor Agitation Market, Revenues & Volume, By Sedatives, 2021 - 2031 |
6.2 Global Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Psychomotor Agitation Market, Revenues & Volume, By Benzodiazepines, 2021 - 2031 |
6.2.3 Global Psychomotor Agitation Market, Revenues & Volume, By Lithium, 2021 - 2031 |
6.2.4 Global Psychomotor Agitation Market, Revenues & Volume, By Antipsychotics, 2021 - 2031 |
6.2.5 Global Psychomotor Agitation Market, Revenues & Volume, By SSRIs, 2021 - 2031 |
6.3 Global Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Psychomotor Agitation Market, Revenues & Volume, By Oral, 2021 - 2031 |
6.3.3 Global Psychomotor Agitation Market, Revenues & Volume, By Injectable, 2021 - 2031 |
6.3.4 Global Psychomotor Agitation Market, Revenues & Volume, By Intravenous, 2021 - 2031 |
6.3.5 Global Psychomotor Agitation Market, Revenues & Volume, By Topical, 2021 - 2031 |
6.4 Global Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Psychomotor Agitation Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Psychomotor Agitation Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.4.4 Global Psychomotor Agitation Market, Revenues & Volume, By Psychiatric Facilities, 2021 - 2031 |
6.4.5 Global Psychomotor Agitation Market, Revenues & Volume, By Research Institutions, 2021 - 2031 |
6.5 Global Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Psychomotor Agitation Market, Revenues & Volume, By Neurological Disorders, 2021 - 2031 |
6.5.3 Global Psychomotor Agitation Market, Revenues & Volume, By Geriatrics, 2021 - 2031 |
6.5.4 Global Psychomotor Agitation Market, Revenues & Volume, By Psychiatric Disorders, 2021 - 2031 |
6.5.5 Global Psychomotor Agitation Market, Revenues & Volume, By Autism Spectrum, 2021 - 2031 |
7 North America Psychomotor Agitation Market, Overview & Analysis |
7.1 North America Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
7.2 North America Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
7.4 North America Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.5 North America Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
7.7 North America Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
8 Latin America (LATAM) Psychomotor Agitation Market, Overview & Analysis |
8.1 Latin America (LATAM) Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
8.4 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
8.5 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
8.6 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
8.7 Latin America (LATAM) Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
9 Asia Psychomotor Agitation Market, Overview & Analysis |
9.1 Asia Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
9.4 Asia Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
9.5 Asia Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
9.6 Asia Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
9.7 Asia Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
10 Africa Psychomotor Agitation Market, Overview & Analysis |
10.1 Africa Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
10.4 Africa Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
10.5 Africa Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
10.6 Africa Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
10.7 Africa Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
11 Europe Psychomotor Agitation Market, Overview & Analysis |
11.1 Europe Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
11.4 Europe Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
11.5 Europe Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
11.6 Europe Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
11.7 Europe Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
12 Middle East Psychomotor Agitation Market, Overview & Analysis |
12.1 Middle East Psychomotor Agitation Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Psychomotor Agitation Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Psychomotor Agitation Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Psychomotor Agitation Market, Revenues & Volume, By Treatment Type, 2021 - 2031 |
12.4 Middle East Psychomotor Agitation Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
12.5 Middle East Psychomotor Agitation Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
12.6 Middle East Psychomotor Agitation Market, Revenues & Volume, By End User, 2021 - 2031 |
12.7 Middle East Psychomotor Agitation Market, Revenues & Volume, By Application, 2021 - 2031 |
13 Global Psychomotor Agitation Market Key Performance Indicators |
14 Global Psychomotor Agitation Market - Export/Import By Countries Assessment |
15 Global Psychomotor Agitation Market - Opportunity Assessment |
15.1 Global Psychomotor Agitation Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Psychomotor Agitation Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
15.3 Global Psychomotor Agitation Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
15.4 Global Psychomotor Agitation Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
15.5 Global Psychomotor Agitation Market Opportunity Assessment, By End User, 2021 & 2031F |
15.6 Global Psychomotor Agitation Market Opportunity Assessment, By Application, 2021 & 2031F |
16 Global Psychomotor Agitation Market - Competitive Landscape |
16.1 Global Psychomotor Agitation Market Revenue Share, By Companies, 2024 |
16.2 Global Psychomotor Agitation Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here